Empagliflozin
- Generic Name
- Empagliflozin
- Brand Names
- Glyxambi, Jardiance, Synjardy, Trijardy
- Drug Type
- Small Molecule
- Chemical Formula
- C23H27ClO7
- CAS Number
- 864070-44-0
- Unique Ingredient Identifier
- HDC1R2M35U
- Background
Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies, for the management of type 2 diabetes mellitus.
...
- Indication
Empagliflozin is indicated as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes, either alone or in combination with metformin or linagliptin. It is also indicated to reduce the risk of cardiovascular death in adult patients with both type 2 diabetes mellitus and established cardiovascular disease, either alone or a...
- Associated Conditions
- Cardiovascular Mortality, Chronic Kidney Disease (CKD), End Stage Renal Disease (ESRD), Hospitalizations, Symptomatic Congestive Heart Failure, Type 2 Diabetes Mellitus, Decreased estimated glomerular filtration rate
- Associated Therapies
- Monotherapy
Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)
- First Posted Date
- 2015-04-13
- Last Posted Date
- 2019-01-03
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 730
- Registration Number
- NCT02414958
- Locations
- 🇺🇸
Rocky Mountain Diabetes and Osteoporosis Center, Idaho Falls, Idaho, United States
🇺🇸Northwest Endo Diabetes Research, LLC, Arlington Heights, Illinois, United States
🇺🇸Office of Dr. Michelle Zaniewski-Singh, Houston, Texas, United States
Effects of Linagliptin in Addition to Empagliflozin on Islet Cell Physiology
- Conditions
- Interventions
- First Posted Date
- 2015-03-30
- Last Posted Date
- 2016-02-24
- Lead Sponsor
- Profil Institut für Stoffwechselforschung GmbH
- Target Recruit Count
- 89
- Registration Number
- NCT02401880
- Locations
- 🇩🇪
Profil Institut für Stoffwechselforschung GmbH, Neuss, Germany
🇩🇪Profil Mainz GmbH & Co. KG, Mainz, Germany
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Male and Female
- Conditions
- Interventions
- First Posted Date
- 2014-10-17
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02266472
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Ingelheim, Germany
Bioequivalence of a Fixed Dose Combination Tablet of Empagliflozin/Metformin Extended Release Compared With Mono Compound Tablets in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2014-09-03
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 30
- Registration Number
- NCT02230995
- Locations
- 🇩🇪
Boehringer Ingelheim Investigational Site, Biberach an der Riss, Germany
Efficacy and Safety of Empagliflozin Versus Sitagliptin in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2014-10-27
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT01984606
Post Prandial Glucose (PPG) Study of Empagliflozin in Japanese Patients With Type 2 Diabetes Mellitus
- First Posted Date
- 2013-09-23
- Last Posted Date
- 2014-12-24
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 60
- Registration Number
- NCT01947855
- Locations
- 🇯🇵
1245.35.002 Boehringer Ingelheim Investigational Site, Shinjyuku-ku, Tokyo, Japan
🇯🇵1245.35.001 Boehringer Ingelheim Investigational Site, Suita-shi, Osaka, Japan
Effect of Empagliflozin Kinetics on Renal Glucose Reabsorption in Patients With Type II Diabetes and Healthy Controls
- Conditions
- Interventions
- First Posted Date
- 2013-06-04
- Last Posted Date
- 2017-05-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 39
- Registration Number
- NCT01867307
- Locations
- 🇺🇸
Boehringer Ingelheim Investigational Site, San Antonio, Texas, United States
Bioequivalence of Empagliflozin and Metformin Given as a Fixed Dose Combination Compared to Single Tablets
- Conditions
- Interventions
- First Posted Date
- 2013-05-01
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 24
- Registration Number
- NCT01844531
- Locations
- 🇩🇪
1276.6.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Equivalence of Resorption of Empagliflozin/Metformin Administered as Combination Tablet Compared With Empagliflozin/Metformin as Single Tablets Administered Together
- Conditions
- Interventions
- First Posted Date
- 2013-03-15
- Last Posted Date
- 2015-07-27
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 48
- Registration Number
- NCT01811953
- Locations
- 🇩🇪
1276.8.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Demonstration of Bioequivalence of Empagliflozin and Metformin Given in One Tablet Compared to the Intake of Single Tablets
- Conditions
- Interventions
- First Posted Date
- 2012-08-27
- Last Posted Date
- 2015-08-31
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 36
- Registration Number
- NCT01672788
- Locations
- 🇩🇪
1276.7.1 Boehringer Ingelheim Investigational Site, Biberach, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.